Skip to main content

Articles

Page 7 of 75

  1. The transmembrane receptor Kremen2 has been reported to participate in the tumorigenesis and metastasis of gastric cancer. However, the role of Kremen2 in non-small cell lung cancer (NSCLC) and the underlying ...

    Authors: Yuxiao Sun, Yu Gao, Mingxin Dong, Jiuzhen Li, Xin Li, Ningning He, Huijuan Song, Manman Zhang, Kaihua Ji, Jinhan Wang, Yeqing Gu, Yan Wang, Liqing Du, Yang Liu, Qin Wang, Hezheng Zhai…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:140
  2. Breast cancer (BC) negatively impacts the health of women worldwide. Circular RNAs (circRNAs) are a group of endogenous RNAs considered essential regulatory factor in BC tumorigenesis and progression. However,...

    Authors: Boxuan Zhou, Jinhua Xue, Runxin Wu, Hongyu Meng, Ruixi Li, Zhaohong Mo, Hang Zhai, Xianyu Chen, Rongqiang Liu, Guie Lai, Xiaohong Chen, Taiyuan Li and Shiyang Zheng
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:138

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2023 42:158

  3. Immune checkpoint blockade (ICB) elicits a strong and durable therapeutic response, but its application is limited by disparate responses and its associated immune-related adverse events (irAEs). Previously, i...

    Authors: Radhika Mishra, Ariunbuyan Sukhbaatar, Shiro Mori and Tetsuya Kodama
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:132
  4. Disulfidptosis, a new form of cell death triggered by disulfide stress, is characterized by the collapse of cytoskeleton proteins and F-actin due to the intracellular accumulation of disulfides. This discovery...

    Authors: Tingjin Zheng, Qingbo Liu, Feiyue Xing, Chong Zeng and Weidong Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:137
  5. Increasing evidence indicates that the tumor microenvironment (TME) is a crucial determinant of cancer progression. However, the clinical and pathobiological significance of stromal signatures in the TME, as a...

    Authors: Jian-Zhong He, Yang Chen, Fa-Min Zeng, Qing-Feng Huang, Hai-Feng Zhang, Shao-Hong Wang, Shuai-Xia Yu, Xiao-Xiao Pang, Ye Liu, Xiu-E Xu, Jian-Yi Wu, Wen-Jun Shen, Zhan-Yu Li, En-Min Li and Li-Yan Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:136
  6. Authors: Chrysostomi Gialeli, Emre Can Tuysuz, Johan Staaf, Safa Guleed, Veronika Paciorek, Matthias Mörgelin, Konstantinos S. Papadakos and Anna M. Blom
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:135

    The original article was published in Journal of Experimental & Clinical Cancer Research 2021 40:258

  7. Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer. Large-scale metabolomic data have associated metabolic alterations with the pathogenesis and progression of renal carcinoma a...

    Authors: Christofer Rupert, Carmela Dell’ Aversana, Laura Mosca, Vittorino Montanaro, Davide Arcaniolo, Marco De Sio, Antonio Bilancio, Lucia Altucci, Wulf Palinski, Roberto Pili and Filomena de Nigris
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:134
  8. Efforts to precisely assess tumor-specific T-cell immune responses still face major challenges, and the potential molecular mechanisms mediating hepatocellular carcinoma (HCC) microenvironment imbalance after ...

    Authors: Zheng-Rong Shi, Yu-Xin Duan, Fang Cui, Zhong-Jun Wu, Mao-Ping Li, Pei-Pei Song, Qi-Ling Peng, Wen-Tao Ye, Kun-Li Yin, Mei-Qing Kang, Yan-Xi Yu, Jian Yang, Wei Tang and Rui Liao
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:133
  9. Hippo signaling was first identified in Drosophila as a key controller of organ size by regulating cell proliferation and anti-apoptosis. Subsequent studies have shown that this pathway is highly conserved in ...

    Authors: Juan Luo, Liang Deng, Hailin Zou, Yibo Guo, Tongyu Tong, Mingli Huang, Gengqiang Ling and Peng Li
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:130
  10. Emerging studies have identified chronic psychological stress as an independent risk factor influencing breast cancer growth and metastasis. However, the effects of chronic psychological stress on pre-metasta...

    Authors: Yifeng Zheng, Neng Wang, Shengqi Wang, Juping Zhang, Bowen Yang and Zhiyu Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:129
  11. Castration-resistant prostate cancer (CRPC) is currently the main challenge for prostate cancer (PCa) treatment, and there is an urgent need to find novel therapeutic targets and drugs. Prohibitin (PHB1) is a ...

    Authors: Junmei Liu, Ranran Zhang, Tong Su, Qianqian Zhou, Lin Gao, Zongyue He, Xin Wang, Jian Zhao, Yuanxin Xing, Feifei Sun, Wenjie Cai, Xinpei Wang, Jingying Han, Ruixi Qin, Laurent Désaubry, Bo Han…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:128
  12. Ferroptosis has been linked to tumor progression and resistance to antineoplastic therapy. Long noncoding RNA (lncRNA) exerts a regulatory role in various biological processes of tumor cells, while the functio...

    Authors: Jianglin Zheng, Qing Zhang, Zhen Zhao, Yue Qiu, Yujie Zhou, Zhipeng Wu, Cheng Jiang, Xuan Wang and Xiaobing Jiang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:127
  13. High grade serous ovarian cancer (HGSOC) is highly lethal, partly due to chemotherapy resistance and limited availability of targeted approaches. Cyclin dependent kinases 12 and 13 (CDK12/13) are promising the...

    Authors: Eleonora Cesari, Alessandra Ciucci, Marco Pieraccioli, Cinzia Caggiano, Camilla Nero, Davide Bonvissuto, Francesca Sillano, Marianna Buttarelli, Alessia Piermattei, Matteo Loverro, Floriana Camarda, Viviana Greco, Maria De Bonis, Angelo Minucci, Daniela Gallo, Andrea Urbani…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:126
  14. Increasing evidence shows that circular RNAs (circRNAs), a novel class of noncoding RNAs, play a crucial role in the development of cancers, including intrahepatic cholangiocarcinoma (iCCA). Nevertheless, thei...

    Authors: Wenwei Liao, Jinpeng Du, Lian Li, Xianquan Wu, Xing Chen, Qingbo Feng, Lin Xu, Xiangzheng Chen, Mingheng Liao, Jiwei Huang, Kefei Yuan and Yong Zeng
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:125

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:55

  15. Authors: Antonio Cigliano, Shanshan Zhang, Silvia Ribback, Sara Steinmann, Marcella Sini, Cindy E. Ament, Kirsten Utpatel, Xinhua Song, Jingxiao Wang, Maria G. Pilo, Fabian Berger, Haichuan Wang, Junyan Tao, Xiaolei Li, Giovanni M. Pes, Serena Mancarella…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:124

    The original article was published in Journal of Experimental & Clinical Cancer Research 2022 41:192

  16. Pancreatic cancer (PC) is one of the most aggressive malignancies worldwide. Increasing evidence suggests that the capacity for self-renewal, proliferation, and differentiation of pancreatic cancer stem cells ...

    Authors: Yutong Zhao, Cheng Qin, Bangbo Zhao, Yuanyang Wang, Zeru Li, Tianyu Li, Xiaoying Yang and Weibin Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:122
  17. The repressor element-1 silencing transcription factor (REST), a master transcriptional repressor, is essential for maintenance, self-renewal, and differentiation in neuroblastoma. An elevated expression of RE...

    Authors: Janardhan Keshav Karapurkar, Min-Seong Kim, Jencia Carminha Colaco, Bharathi Suresh, Neha Sarodaya, Dong-Ho Kim, Chang-Hwan Park, Seok-Ho Hong, Kye-Seong Kim and Suresh Ramakrishna
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:121
  18. MET-driven acquired resistance is emerging with unanticipated frequency in patients relapsing upon molecular therapy treatments. However, the determination of MET amplification remains challenging using both stan...

    Authors: Francesca Bersani, Francesca Picca, Deborah Morena, Luisella Righi, Francesca Napoli, Mariangela Russo, Daniele Oddo, Giuseppe Rospo, Carola Negrino, Barbara Castella, Marco Volante, Angela Listì, Vanessa Zambelli, Federica Benso, Fabrizio Tabbò, Paolo Bironzo…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:120
  19. Prostate Cancer (PCa) represents one of the most commonly diagnosed neoplasms in men and is associated with significant morbidity and mortality. Therapy resistance and significant side effects of current treat...

    Authors: Achinto Saha, Shengyuan Zhao, Austin Kindall, Carly Wilder, Chelsea A. Friedman, Rachel Clark, George Georgiou, Everett Stone, Dawit Kidane and John DiGiovanni
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:119
  20. The failure of novel therapies effective in preclinical animal models largely reflects the fact that current models do not really mimic the pathological/therapeutic features of glioblastoma (GBM), in which the...

    Authors: Feng Liu, Qian Zhou, Hai-feng Jiang, Ting-ting Zhang, Cheng Miao, Xiao-hong Xu, Jia-xing Wu, Song-lin Yin, Shi-jie Xu, Jing-yi Peng, Pan-pan Gao, Xuan Cao, Feng Pan, Ximiao He and Xiao Qian Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:118
  21. There are few effective medications for treating colorectal cancer and liver metastases (CRLM). The interactions among glycolysis, epithelial-mesenchymal transition (EMT), and immune microenvironment contribut...

    Authors: Li Long, Wei Xiong, Fenwang Lin, Jiazhen Hou, Guihua Chen, Taoxing Peng, Yihao He, Rui Wang, Qin Xu and Yongzhuo Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:117
  22. Bronchial premalignant lesions (PMLs) are composed primarily of cells resembling basal epithelial cells of the airways, which through poorly understood mechanisms have the potential to progress to lung squamou...

    Authors: Boting Ning, Andrew M. Tilston-Lunel, Justice Simonetti, Julia Hicks-Berthet, Adeline Matschulat, Roxana Pfefferkorn, Avrum Spira, Matthew Edwards, Sarah Mazzilli, Marc E. Lenburg, Jennifer E. Beane and Xaralabos Varelas
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:116
  23. Patients with colorectal metastatic disease have a poor prognosis, limited therapeutic options, and frequent development of resistance. Strategies based on tumor-derived organoids are a powerful tool to assess...

    Authors: Lars Henrik Jensen, Silvia Regina Rogatto, Jan Lindebjerg, Birgitte Havelund, Cecilie Abildgaard, Luisa Matos do Canto, Chris Vagn-Hansen, Claus Dam, Søren Rafaelsen and Torben Frøstrup Hansen
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:115
  24. Current clinical and observational evidence supports the EXTREME regimen as one of the standards of care for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) followed by the ...

    Authors: Kohei Okuyama, Tomofumi Naruse and Souichi Yanamoto
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:114
  25. Methylation of the p16 promoter resulting in epigenetic gene silencing—known as p16 epimutation—is frequently found in human colorectal cancer and is also common in normal-appearing colonic mucosa of aging indivi...

    Authors: Li Yang, Xiaomin Chen, Christy Lee, Jiejun Shi, Emily B. Lawrence, Lanjing Zhang, Yumei Li, Nan Gao, Sung Yun Jung, Chad J. Creighton, Jingyi Jessica Li, Ya Cui, Sumimasa Arimura, Yunping Lei, Wei Li and Lanlan Shen
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:113
  26. Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA re...

    Authors: Genevieve Dall, Cassandra J. Vandenberg, Ksenija Nesic, Gayanie Ratnayake, Wenying Zhu, Joseph H. A. Vissers, Justin Bedő, Jocelyn Penington, Matthew J. Wakefield, Damien Kee, Amandine Carmagnac, Ratana Lim, Kristy Shield-Artin, Briony Milesi, Amanda Lobley, Elizabeth L. Kyran…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:112
  27. Chemoresistance is the main reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and compounds to reverse chemotherapeutic resistance.

    Authors: Tianxing Zhou, Yongjie Xie, Xupeng Hou, Weiwei Bai, Xueyang Li, Ziyun Liu, Quan Man, Jingyan Sun, Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yifei Wang, Hongwei Wang, Wenna Jiang, Song Gao, Tiansuo Zhao…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:111
  28. Ufm1-specific ligase 1 (Ufl1) and Ufm1-binding protein 1 (Ufbp1), as putative targets of ubiquitin-fold modifier 1 (Ufm1), have been implicated in several pathogenesis-related signaling pathways. However, litt...

    Authors: Fanghui Chen, Le Sheng, Tianci Zhou, Li Yan, Reid Loveless, Honglin Li, Yong Teng and Yafei Cai
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:110
  29. We have previously reported that extracellular vesicles (EVs) derived from osteoblastic, osteoclastic and mixed prostate cancer cells promote osteoclast differentiation and inhibit osteoblast differentiation v...

    Authors: Lijuan Yu, Bingdong Sui, Xin Zhang, Jiayun Liu, Xiaoke Hao and Lei Zheng
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:109
  30. Tumor cells display augmented capability to maintain endoplasmic reticulum (ER) homeostasis and hijack ER stress pathway for malignant phenotypes under microenvironmental stimuli. Metabolic reprogramming is a ...

    Authors: Chenyu Hu, Zechang Xin, Xiaoyan Sun, Yang Hu, Chunfeng Zhang, Rui Yan, Yuying Wang, Min Lu, Jing Huang, Xiaojuan Du, Baocai Xing and Xiaofeng Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:108
  31. Ovarian cancer (OC) is known for exhibiting low response rates to immune checkpoint inhibitors that activate T cells. However, immunotherapies that activate B cells have not yet been extensively explored and m...

    Authors: Jonathan Zorea, Yair Motro, Roei D. Mazor, Yifat Koren Carmi, Ziv Shulman, Jamal Mahajna, Jacob Moran-Gilad and Moshe Elkabets
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:107
  32. The malaria protein VAR2CSA binds oncofetal chondroitin sulfate (ofCS), a unique chondroitin sulfate, expressed on almost all mammalian cancer cells. Previously, we produced a bispecific construct targeting of...

    Authors: Nanna Skeltved, Mie A. Nordmaj, Nicolai T. Berendtsen, Robert Dagil, Emilie M. R. Stormer, Nader Al-Nakouzi, Ke Jiang, Alexandra Aicher, Christopher Heeschen, Tobias Gustavsson, Swati Choudhary, Ismail Gögenur, Jan P. Christensen, Thor G. Theander, Mads Daugaard, Ali Salanti…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:106
  33. High-intensity chemotherapy regimens are often used in adult T-cell lymphoblastic lymphoma (T-LBL) patients. Nevertheless, the response rate remains unsatisfactory due to emergence of chemoresistance. Growing ...

    Authors: Wei-Juan Huang, Song-Bin Guo, Hui Shi, Xin-Ling Li, Yong Zhu, Mei Li, Li-Yan Song, Rong-Min Yu, Qing-Qing Cai and Xiao-Peng Tian
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:105
  34. Authors: Zixian Huang, Xi Rui, Chen Yi, Yongju Chen, Rui Chen, Yancan Liang, Yan Wang, Weicheng Yao, Xiaoding Xu and Zhiquan Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:104

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:60

  35. Altered metabolism is a hallmark of cancer and presents a vulnerability that can be exploited in cancer treatment. Regulated cell death (RCD) plays a crucial role in cancer metabolic therapy. A recent study ha...

    Authors: Peijie Zheng, Chuntao Zhou, Yuemin Ding and Shiwei Duan
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:103
  36. Authors: Christopher B. Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D. Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lipkowitz, Alexandra Zimmer, Jung-min Lee, Miroslava Pavelova, Erin N. Villanueva, Kathryn Trewhitt…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:102

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:76

  37. Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with an appalling overall survival of less than 5% (Zimmerman et al. J Thor Oncol 14:768-83, 2019). Patients typically respond to front line...

    Authors: Jasmine Chen, Aleks C. Guanizo, W. Samantha N. Jakasekara, Chaitanya Inampudi, Quinton Luong, Daniel J. Garama, Muhammad Alamgeer, Nishant Thakur, Michael DeVeer, Vinod Ganju, D. Neil Watkins, Jason E. Cain and Daniel J. Gough
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:100
  38. MiT-Renal Cell Carcinoma (RCC) is characterized by genomic translocations involving microphthalmia-associated transcription factor (MiT) family members TFE3, TFEB, or MITF. MiT-RCC represents a specific subtype o...

    Authors: Martin Lang, Laura S. Schmidt, Kelli M. Wilson, Christopher J. Ricketts, Carole Sourbier, Cathy D. Vocke, Darmood Wei, Daniel R. Crooks, Youfeng Yang, Benjamin K. Gibbs, Xiaohu Zhang, Carleen Klumpp-Thomas, Lu Chen, Rajarshi Guha, Marc Ferrer, Crystal McKnight…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:99
  39. Authors: Min Deng, Long Zhang, Wenying Zheng, Jiale Chen, Nan Du, Meiqi Li, Weiqing Chen, Yonghong Huang, Ning Zeng, Yuanbin Song and Yongming Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:98

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:9

  40. Although molecular targets such as HER2, TP53 and PIK3CA have been widely studied in esophageal cancer, few of them were successfully applied for clinical treatment. Therefore, it is urgent to discover novel a...

    Authors: Xuechao Jia, Penglei Wang, Chuntian Huang, Dengyun Zhao, Qiong wu, Bingbing Lu, Wenna Nie, Limeng Huang, Xueli Tian, Pan li, Kyle Vaughn Laster, Yanan Jiang, Xiang Li, Honglin Li, Zigang Dong and Kangdong Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:97
  41. Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers worldwide, but current treatment options remain limited and cause serious life-threatening side effects. Aberrant FGFR4 signaling has...

    Authors: Yiqi Yang, Yibo Zhang, Jieqiong Cao, Zijian Su, Fu Li, Peiguang Zhang, Bihui Zhang, Rongzhan Liu, Linhao Zhang, Junye Xie, Jingsheng Li, Jinting Zhang, Xiaojia Chen and An Hong
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:96
  42. Colorectal cancer (CRC) is the third most lethal cancer in the world, and its incidence is steadily rising. In this study, we investigated the induction of humoral immunity by a phytogalactolipid enriched frac...

    Authors: Han-Huei Lin, Yi-Shin Wu, Ting-Yan Jian, Jia-Yun Liao, Meng-Ting Chang, Lie-Fen Shyur and Yu-Ling Lin
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:95
  43. Malignant breast cancer (BC) remains incurable mainly due to the cancer cell metastasis, which is mostly related to the status of Estrogen receptor alpha (ERα). However, our understanding of the mechanisms thr...

    Authors: Jinhui Lü, Qian Zhao, Yuefan Guo, Danni Li, Heying Xie, Cuicui Liu, Xin Hu, Suling Liu, Zhaoyuan Hou, Xunbin wei, Deyou Zheng, Richard G. Pestell and Zuoren Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:93
  44. One of the key limitations of targeted cancer therapies is the rapid onset of therapy resistance. Taking BRAF-mutant melanoma as paradigm, we previously identified the lipogenic regulator SREBP-1 as a central ...

    Authors: Ali Talebi, Vincent de Laat, Xander Spotbeen, Jonas Dehairs, Florian Rambow, Aljosja Rogiers, Frank Vanderhoydonc, Lara Rizotto, Mélanie Planque, Ginevra Doglioni, Sahar Motamedi, David Nittner, Tania Roskams, Patrizia Agostinis, Oliver Bechter, Veerle Boecxstaens…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:92
  45. Authors: Chunyan Gu, Yajun Wang, Lulin Zhang, Li Qiao, Shanliang Sun, Miaomiao Shao, Xiaozhu Tang, Pinggang Ding, Chao Tang, Yuhao Cao, Yanyan Zhou, Mengjie Guo, Rongfang Wei, Nianguang Li, Yibei Xiao, Jinao Duan…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:91

    The original article was published in Journal of Experimental & Clinical Cancer Research 2022 41:11

Annual Journal Metrics

  • 2022 Citation Impact
    11.3 - 2-year Impact Factor
    11.5 - 5-year Impact Factor
    1.870 - SNIP (Source Normalized Impact per Paper)
    2.413 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage 
    3,003,080 downloads
    3,022 Altmetric mentions